| Literature DB >> 34094896 |
Jianhao Huang1,2, Muye Song1,3, Hongyan Shi1,4, Ziyang Huang1,2, Shujie Wang1,4, Ying Yin1, Yijie Huang1, Jialin Du1, Sanming Wang1, Yongchen Liu1, Zeyu Wu1.
Abstract
Large-volume central lymph node metastasis (large-volume CLNM) is associated with high recurrence rate in papillary thyroid carcinoma (PTC) patients. However, sensitivity in investigating large-volume CLNM on preoperative ultrasonography (US) is not high. The aim of this study is to investigate the clinical factors associated with large-volume CLNM in clinical N0 PTC patients. We reviewed 976 PTC patients undergoing total thyroidectomy with central lymph node dissection during 2017 to 2019. The rate of large-volume LNM was 4.1% (40 of 967 patients). Multivariate analysis showed that male gender and young age (age<45 years old) were independent risk factors for large-volume CLNM with odds ratios [(OR), 95% confidence interval (CI)] of 2.034 (1.015-4.073) and 2.997 (1.306-6.876), respectively. In papillary thyroid microcarcinoma (PTMC), capsule invasion was associated with large-volume CLNM with OR (95% CI) of 2.845 (1.110-7.288). In conventional papillary thyroid cancer (CPTC), tumor diameter (>2cm) was associated with large-volume CLNM, with OR (95% CI) 3.757 (1.061-13.310), by multivariate analysis. In ROC curve analysis on the diameter of the CPTC tumor, the Area Under Curve (AUC) =0.682(p=0.013), the best cut-off point was selected as 2.0cm. In conclusion, male gender and young age were predictors for large-volume CLNM of cN0 PTC. cN0 PTMC patient with capsule invasion and cN0 CPTC patient with tumor diameter >2cm were correlated with large-volume CLNM. Total thyroidectomy with central lymph node dissection may be a favorable primary treatment option for those patients.Entities:
Keywords: capsule invasion; central lymph node metastasis; conventional papillary thyroid cancer; total thyroidectomy; tumor diameter
Year: 2021 PMID: 34094896 PMCID: PMC8170408 DOI: 10.3389/fonc.2021.574774
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Clinicopathological characteristics and univariate analysis of PTC patients (n=364).
| Small-volume (n=324) | Large-volume (n=40) | p-value | |
|---|---|---|---|
| Gender | 0.017* | ||
| Male | 108 | 21 | |
| Female | 216 | 19 | |
| Age | 0.046* | ||
| <45 | 190 | 30 | |
| ≥45 | 134 | 10 | |
| Bilateral tumors | 0.094 | ||
| Bilateral | 76 | 14 | |
| Unilateral | 248 | 26 | |
| Multifocal tumor | 0.754 | ||
| Multifocal | 103 | 18 | |
| single | 221 | 22 | |
| Hashimoto’s thyroiditis | 0.157 | ||
| Yes | 62 | 4 | |
| No | 262 | 36 | |
| Nodule | |||
| Goiter | 0.049* | ||
| Yes | 87 | 5 | |
| No | 237 | 35 | |
| Marked Hypoechoic | 0.745 | ||
| Yes | 266 | 32 | |
| No | 58 | 8 | |
| Margin | 0.207 | ||
| Irregular | 276 | 31 | |
| Regular | 48 | 9 | |
| Shape | 0.167 | ||
| Well-defined | 46 | 9 | |
| Non-well-defined | 278 | 31 | |
| Capsule Invasion | 0.003* | ||
| Yes | 70 | 17 | |
| No | 254 | 23 | |
| ETE** | 0.001* | ||
| Yes | 43 | 13 | |
| No | 281 | 27 |
*statistically significance; **extrathyroidal extension.
Multivariate analysis of the risk factors of PTC.
| Sig. | OR (95% CI) | |
|---|---|---|
| Gender | 0.045 | 2.034 (1.015-4.073) |
| Age | 0.010 | 2.997 (1.306-6.876) |
| Capsule Invasion | 0.284 | 0.561 (0.194-1.616) |
| ETE* | 0.136 | 0.408 (0.125-1.326) |
| Nodule goiter | 0.111 | 2.254 (0.829-6.130) |
*extrathyroidal extension.
Clinicopathological characteristics and univariate analysis of PTMC patients (n=232).
| Small-volume (n=210) | Large-volume (n=22) | p-value | |
|---|---|---|---|
| Gender | 0.028* | ||
| Male | 74 | 13 | |
| Female | 136 | 9 | |
| Age | 0.184 | ||
| <45 | 122 | 16 | |
| ≥45 | 88 | 6 | |
| Bilateral tumors | 0.292 | ||
| Bilateral | 46 | 7 | |
| Unilateral | 164 | 15 | |
| Multifocal tumor | 0.043* | ||
| Multifocal | 61 | 11 | |
| single | 149 | 11 | |
| Hashimoto’s thyroiditis | 0.964 | ||
| Yes | 39 | 4 | |
| No | 171 | 18 | |
| Nodule | 0.226 | ||
| Goiter | |||
| Yes | 53 | 3 | |
| No | 157 | 19 | |
| Margin | 0.748 | ||
| Irregular | 179 | 20 | |
| Regular | 31 | 2 | |
| Shape | 1.00 | ||
| Well-defined | 30 | 3 | |
| Non-well-defined | 180 | 19 | |
| Marked Hypoechoic | 0.115 | ||
| Yes | 173 | 21 | |
| No | 37 | 1 | |
| Invasion | 0.004* | ||
| Yes | 40 | 12 | |
| No | 170 | 10 | |
| ETE** | 0.079 | ||
| Yes | 28 | 6 | |
| No | 182 | 16 | |
| Size of tumors | 0.916 | ||
| >0.5 | 136 | 14 | |
| ≤0.5 | 74 | 8 |
*statistically significance; **extrathyroidal extension.
Multivariate analysis of the risk factors of PTMC.
| Sig. | OR (95% CI) | |
|---|---|---|
| Gender | 0.123 | 2.080 (0.819-5.281) |
| Multifocality | 0.121 | 2.064 (0.826-5.160) |
| Capsule Invasion | 0.029 | 2.845 (1.110-7.288) |
Clinicopathological characteristics and univariate analysis of CPTC patients (n=132).
| Small-volume (n=114) | Large-volume (n=18) | p-value | |
|---|---|---|---|
| Gender | 0.216 | ||
| Male | 34 | 8 | |
| Female | 80 | 10 | |
| Age | 0.141 | ||
| <45 | 68 | 14 | |
| ≥45 | 46 | 4 | |
| Bilateral tumors | 0.270 | ||
| Bilateral | 30 | 7 | |
| Unilateral | 84 | 11 | |
| Multifocal tumor | 0.754 | ||
| Multifocal | 40 | 7 | |
| single | 74 | 11 | |
| Hashimoto’s thyroiditis | 0.042* | ||
| Yes | 19 | 0 | |
| No | 91 | 18 | |
| Nodule | |||
| Goiter | 0.406 | ||
| Yes | 34 | 16 | |
| No | 80 | 2 | |
| Marked Hypoechoic | 0.048* | ||
| Yes | 93 | 11 | |
| No | 12 | 7 | |
| Margin | 0.022* | ||
| Irregular | 97 | 11 | |
| Regular | 17 | 7 | |
| Shape | 0.08 | ||
| Well-defined | 16 | 6 | |
| Non-well-defined | 98 | 12 | |
| Capsule Invasion | 0.27 | ||
| Yes | 30 | 7 | |
| No | 84 | 11 | |
| ETE** | 0.013* | ||
| Yes | 15 | 7 | |
| No | 99 | 11 | |
| Size of tumors | 0.005* | ||
| >2cm | 16 | 8 | |
| ≤2cm | 98 | 10 |
*statistically significance; **extrathyroidal extension.
Multivariate analysis of the risk factors of CPTC.
| Sig. | OR (95% CI) | |
|---|---|---|
| Hashimoto’s | 0.998 | 0.00 |
| Margin | 0.596 | 0.649 (0.131-3.219) |
| Shape | 0.419 | 0.533 (0.116-2.452) |
| Diameter | 0.040 | 3.757 (1.061-13.310) |
| ETE* | 0.072 | 3.194 (0.900-11.332) |
*extrathyroidal extension.
Figure 1ROC curve analysis of the cutoff point for diameter of the CPTC tumor.